Physician profile
Steven Smith
NPI 1881689222
$2,194.71
in general payments reported to CMS, 2019-2025
14 companies · $213 in 2025
The $213 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $375 · 2021: $1,209 · 2022: $45.36 · 2023: $192 · 2024: $161 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426 · Consulting Fee: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.64 |
| Consulting Fee | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $862.00 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $355.83 | 2020 | |
| Vifor Pharma, INC. | $242.86 | 2021-2025 | Veltassa |
| Glaxosmithkline, LLC. | $140.00 | 2023 | Benlysta |
| Zimmer Biomet Holdings, INC. | $124.49 | 2021 | |
| Amgen INC. | $110.65 | 2021-2024 | Parsabiv, Tavneos |
| Calliditas Therapeutics US INC. | $103.74 | 2024-2025 | Tarpeyo |
| Ceribell, INC. | $80.74 | 2024-2025 | Pocket Eeg Device |
| Nxstage Medical, INC. | $60.09 | 2025 | Pureflow Sl, Liberty Select Cycler, Nxstage System One |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.14 | 2022 | |
| Sandoz INC. | $25.44 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.52 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $18.99 | 2020 | |
| Fresenius USA Marketing, INC. | $14.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.